Research programme: complement component 3a (C3a) receptor modulators - UniQuest

Drug Profile

Research programme: complement component 3a (C3a) receptor modulators - UniQuest

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Small molecules
  • Mechanism of Action Complement C3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Metabolic disorders

Most Recent Events

  • 04 Aug 2016 Research programme: complement component 3a (C3a) receptor modulators - UniQuest is available for licensing - http://uniquest.com.au/filething/get/11785/c3a%20Modulators%20UniQuest.pdf
  • 04 Aug 2016 Preclinical trials in Inflammation in Australia (PO)
  • 04 Aug 2016 Preclinical trials in Metabolic disorders in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top